Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes

Diabetes Care

Volumn 36, Issue 1, 2013, Pages 63-69

  Hoerger, Thomas J ^a   Schillie, Sarah ^b   Wittenborn, John S ^c   Bradley, Christina L ^a   Zhou, Fangjun ^b   Byrd, Kathy ^b   Murphy, Trudy V ^b  

^a RTI INTERNATIONAL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

ACTIVE IMMUNIZATION; ARTICLE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; HEALTH CARE COST; HEALTH PROGRAM; HEPATITIS B; INFECTION RATE; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UNITED STATES;

ADULT; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; FEMALE; HEPATITIS B; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; VACCINATION; YOUNG ADULT;

EID: 84872025206     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0759     Document Type: Article

References (26)

1. Centers for Disease Control and Prevention (CDC). Hepatitis B vaccination - United States, 1982-2002. MMWR Morb Mortal Wkly Rep 2002;51:549-552, 563
2. Centers for Disease Control and Prevention (CDC). Viral hepatitis statistics and surveillance, United States 2010. Available at http://www.cdc.gov/hepatitis/Statistics/2010Surveillance/PDFs/ 2010HepSurveillanceRpt.pdf. Accessed 6 August 2012
3. Daniels D, Grytdal S, Wasley A; Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ 2009;58:1 -27
4. Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011;60:1709-1711
5. Murphy T. Hepatitis B vaccination for adults with diabetes: summary of considerations. Advisory Committee on Immunization Practices (ACIP). 25 October 2011
6. Schillie S, Smith E, Reilly M, Murphy T. Odds of acute hepatitis B among persons with diabetes at eight emerging infections program sites. Advisory Committee on Immunization Practices. 25 October 2011.
7. Thompson ND, Perz JF. Eliminating the blood: ongoing outbreaks of hepatitis B virus infection and the need for innovative glucose monitoring technologies. J Diabetes Sci Tech 2009;3:283-288
8. Zhou F, Euler GL, McPhee SJ, et al. Economic analysis of promotion of hepatitis B vaccinations among Vietnamese-American children and adolescents in Houston and Dallas. Pediatrics 2003;111:1289-1296
9. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995;274:1201-1208
10. Kim SY, Billah K, Lieu TA, Weinstein MC. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. Am J Prev Med 2006;30:498-506
11. Jiles R. Epidemiology of Acute Hepatitis B. Atlanta, GA, Division of Viral Hepatitis, Centers for Disease Control and Prevention, 2010
12. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States.Med Decis Making 2006;26:410-420
13. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. CDC vaccine price list: adult vaccine price list [Internet], 2011. Available at http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list. htm. Accessed 9 May 2011
14. Miriti MK, Billah K, Weinbaum C, et al. Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the U.S. Public Health Rep 2008;123:504-513
15. Freed GL, Clark SJ, Cowan AE, Coleman MS. Primary care physician perspectives on providing adult vaccines. Vaccine 2011;29:1850-1854
16. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, Oxford University Press, 1996
17. Tambour M, Zethraeus N. Bootstrap confidence intervals for cost-effectiveness ratios: some simulation results. Health Econ 1998;7:143-147
18. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010;33:1872-1894
19. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007;44:1280-1288
20. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007;25:8326-8337
21. Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine 2009;27:4891-4904
22. Reilly ML, Poissant T, Vonderwahl CW, Gerard K, Murphy TV. Incidence of acute hepatitis B among adultswith and without diabetes, 2009-2010. Abstract presented at the 49th Annual Meeting of Infectious Diseases Society of America, 20-23 October 2011, Boston, Massachusetts.
23. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995;20:992-1000
24. Kondo Y, Tsukada K, Takeuchi T, et al. High carrier rate after hepatitis B virus infection in the elderly. Hepatology 1993;18:768-774
25. Centers for Disease Control and Prevention (CDC). Notes from the field: deaths from acute hepatitis B virus infection associated with assisted blood glucose monitoring in an assisted-living facilitydNorth Carolina, August-October 2010. MMWR Morb Mortal Wkly Rep 2011;60:182
26. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010;59:1410-1415